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programming language, using a 3-dimensional transition
matrix, where the third dimension represents time spent
in the current state. The ability of R to manipulate n-
dimensional numeric arrays allowed the complex model
to be easily implemented. RESULTS: The use of a semi-
Markov process to model cost-effectiveness in epilepsy
allowed the reported natural history of the condition to
be accurately reﬂected. This was achieved efﬁciently and
transparently using the R statistical programming lan-
guage. Furthermore, the alternative (and commonly 
used) assumption of ﬁxed transition probabilities with
respect to time generated important differences in cost-
effectiveness results compared to the semi-Markov
process. CONCLUSIONS: Semi-Markov process models
may be useful in modeling a wide range of treatment
processes. By adding further dimensions to the transition
matrix, the transition probabilities could be made depen-
dant on other aspects of patients’ history providing a
useful alternative to discrete event simulation, where
increased speed of execution will aid probabilistic mod-
eling.
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OBJECTIVES: To compare the analytic judgements, data
and assumptions of different models used in the economic
evaluation of inﬂiximab, one of a new class of drugs for
rheumatoid arthritis (RA). The purpose was to under-
stand why different models give such varying results.
METHODS: A detailed assessment was made of three
models, one submitted (in a reimbursement dossier) by
the manufacturer, one produced by an independent aca-
demic group and one published in the literature. Factors
considered included the key data inputs, assumptions
about the sequencing of treatments for RA, the estima-
tion of cost offsets and the modelling of the maintenance
of treatment effect for patients continuing or discontinu-
ing inﬂiximab. RESULTS: Two of the models, although
embodying different methodological approaches, gave
fairly similar results (approximately £30,000–£40,000
cost per additional quality-adjusted life-year gained). The
third model, by the independent academic group, gave
much higher estimates, around £100,000 per QALY. The
differences were mainly because of the assumptions about
the positioning of inﬂiximab in the treatment sequence
and assumptions about the long-term effect of therapy.
CONCLUSIONS: Economic models of treatments for
rheumatoid arthritis incorporate several key analytic
judgements, which can have major impacts on cost-effec-
tiveness. Two of the three models examined gave similar
results, which suggests that consensus can be reached on
several of the main methodological issues.
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OBJECTIVES: Decision analytic models relate health
outcomes in a speciﬁc health state with the costs arisen
in this health state. In most of the decision analytic
models we will ﬁnd the option that people will die either
due to a speciﬁc disease or due to other unspeciﬁed
causes. Treatment costs in the last two years before dying
are exceptionally high. Applying the health state costs to
a patient who is dying will underestimate the true costs.
Additional costs should be applied to correct for this
potential bias. This will present a methodological and
pragmatical approach to estimate costs due to dying 
of a disease speciﬁc cause and unspeciﬁed causes.
METHODS: Age-speciﬁc and non age-speciﬁc costs were
calculated. Dying of unspeciﬁed causes revealed to the
most common causes for dying reﬂecting a background
mortality. To assess the disease speciﬁc costs of dying—
in our case for hepatitis C virus associated diseases; rele-
vant causes of dying have been identiﬁed. Principle of all
cost calculations was the combination of length of termi-
nal hospital stay multiplied by per diem costs. RESULTS:
Over the age of 15 years costs of dying are similar for
disease-speciﬁc causes and unspeciﬁed causes with a range
between €2.133 and €3.701. In the age group between 0
and 4 years costs for unspeciﬁed causes are about €7.645,
in the age group between 5 and 14 years costs are €8.011.
Hepatitis C Virus associated costs for both age groups are
€19.987, respectively €13.018. CONCLUSIONS: The
described pragmatical approach just considers additional
costs in consequence of the last inpatient treatment before
death. Therefore costs are still underestimated. Main
advantage of the described approach will be the applica-
bility to different decision analytic models.
METHODOLOGICAL ISSUES—Other Studies
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OBJECTIVES: The purpose of this study was to deter-
mine whether short courses offered by ISPOR at its
Annual Meeting are a cost-effective means of education
and enhancing meeting attendance, or if the type, com-
plexity, number, or duration of the courses should be
changed. METHOD: Four different survey techniques
